In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.23 below Teva Pharmaceutical Industries Limited average.

Within Major Pharmaceutical Preparations industry 408 other companies have achieved higher Quick Ratio than Teva Pharmaceutical Industries Limited in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 2810 to 3075.

Explain Quick Ratio?
How much Cash & cash equivalents TEVA�s has?
What are TEVA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TEVA Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	31.68 %	20.96 %	-95.47 %	-17.83 %	-7.9 %
Y / Y Cash & cash equivalent Change	69.13 %	120.45 %	7.76 %	-33.62 %	-4.3 %
Quick Ratio MRQ	0.23	0.28	0.25	0.19	0.18
TEVA's Total Ranking	# 3075	# 2810	# 2936	# 2913	# 2820
Seq. Current Liabilities Change	15.52 %	-3.72 %	22.17 %	-3.09 %	6.12 %
Seq. Cash & cash equivalent Change	-2.3 %	5.2 %	61.42 %	1.94 %	27.34 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 409
Healthcare Sector	# 802
Overall Market	# 3075

Quick Ratio Statistics
High	Average	Low
1.73	0.33	0.01
(Dec 31 2015)		(Mar 31 2024)

Financial Statements
Teva Pharmaceutical Industries Limited's Current Liabilities	$ 15,646 Millions	Visit TEVA's Balance sheet
Teva Pharmaceutical Industries Limited's Cash & cash equivalent	$ 3,655 Millions	Visit TEVA's Balance sheet
Source of TEVA's Sales		Visit TEVA's Sales by Geography

Cumulative Teva Pharmaceutical Industries Limited's Quick Ratio

TEVA's Quick Ratio for the trailling 12 Months

TEVA Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-84.25 %	-85.37 %	-92.53 %	0.18 %	1.84 %
Y / Y Cash & cash equivalent TTM Growth	25.56 %	10.28 %	-18.97 %	-20.64 %	-2.32 %
Quick Ratio TTM	0.24	0.23	0.2	0.03	0.03
Total Ranking TTM	# 4087	# 3224	# 3154	# 3311	# 3200
Seq. Current Liabilities TTM Growth	7.38 %	4.82 %	-85.9 %	-0.72 %	-0.29 %
Seq. Cash & cash equivalent TTM Growth	12.81 %	21.25 %	2.73 %	-10.65 %	-0.92 %

Quick ratio ranking by company, industry and sector >> Back to TEVA Financial Strength Comparisons >> Go to Compare TEVA Quick Ratio to its Competitors

On the trailing twelve months basis TEVA Cash & cash equivalent soared by 69.13 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Teva Pharmaceutical Industries Limited's Quick Ratio to 0.24, above TEVA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 442 other companies have achieved higher Quick Ratio than Teva Pharmaceutical Industries Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3224 to 4087.

Explain Quick Ratio?
How much Cash & cash equivalents TEVA�s has?
What are TEVA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 443
Healthcare Sector	# 908
Within the Market	# 4087

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.39	0.17	0.05
(Jun 30 2016)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Pfizer Inc	0.64	$ 20,881.000 Millions	$ 32,646.000 Millions
Enanta Pharmaceuticals Inc	0.62	$ 33.419 Millions	$ 54.166 Millions
60 Degrees Pharmaceuticals Inc	0.61	$ 1.023 Millions	$ 1.685 Millions
Eton Pharmaceuticals Inc	0.59	$ 26.845 Millions	$ 45.124 Millions
Kura Oncology Inc	0.59	$ 70.242 Millions	$ 118.193 Millions
Allarity Therapeutics Inc	0.59	$ 16.982 Millions	$ 28.579 Millions
Bristol myers Squibb Company	0.59	$ 11,067.000 Millions	$ 18,659.000 Millions
Prestige Consumer Healthcare Inc	0.58	$ 89.127 Millions	$ 153.806 Millions
Biora Therapeutics Inc	0.57	$ 21.906 Millions	$ 38.687 Millions
Matinas Biopharma Holdings Inc	0.56	$ 0.761 Millions	$ 1.350 Millions
Karyopharm Therapeutics Inc	0.56	$ 75.225 Millions	$ 134.233 Millions
Journey Medical Corp	0.56	$ 25.643 Millions	$ 45.770 Millions
Nektar Therapeutics	0.55	$ 39.267 Millions	$ 70.985 Millions
Supernus Pharmaceuticals inc	0.52	$ 180.145 Millions	$ 347.378 Millions
Citius Oncology Inc	0.50	$ 16.564 Millions	$ 33.152 Millions
Verrica Pharmaceuticals Inc	0.50	$ 11.198 Millions	$ 22.442 Millions
Aytu Biopharma Inc	0.48	$ 26.308 Millions	$ 54.659 Millions
Jupiter Neurosciences Inc	0.47	$ 1.522 Millions	$ 3.251 Millions
Aeon Biopharma inc	0.47	$ 3.431 Millions	$ 7.342 Millions
Evolus Inc	0.46	$ 45.170 Millions	$ 98.731 Millions
Biomarin Pharmaceutical Inc	0.45	$ 874.005 Millions	$ 1,927.164 Millions
Pds Biotechnology Corp	0.45	$ 5.596 Millions	$ 12.377 Millions
Biofrontera Inc	0.44	$ 4.659 Millions	$ 10.541 Millions
Beyondspring Inc	0.43	$ 10.361 Millions	$ 23.834 Millions
Organon and Co	0.43	$ 1,132.000 Millions	$ 2,616.000 Millions
Gossamer Bio Inc	0.41	$ 57.026 Millions	$ 137.783 Millions
Bausch Health Companies Inc	0.39	$ 1,825.000 Millions	$ 4,687.000 Millions
Johnson and Johnson	0.38	$ 21,094.000 Millions	$ 54,895.000 Millions
Ultragenyx Pharmaceutical Inc	0.36	$ 125.000 Millions	$ 351.000 Millions
Vanda Pharmaceuticals Inc	0.34	$ 56.119 Millions	$ 164.026 Millions

Date modified: 2026-08-12T20:54:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.